

The original disclosure in Japanese was released on Oct. 23, 2012 at 15:30 (GMT+9).

To whom it may concern,

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo (1st section) and Osaka (1st section)
Securities code: 2531
Company representative: Toshio Kakimoto, President
Inquiries: Takuya Kakemi, General Manager of
Financial & Investor Relations Dept.
TEL: (075)241-5124

Revision of Consolidated Business Results Forecast for the First Half of the Fiscal Year Ending March 31, 2013

Kyoto, Japan—Takara Holdings announced revisions to the business results forecast for the first half of the fiscal year ending March 31, 2013 (from April 1, 2012, to March 31, 2013) that it released on May 9, 2012, as stated below. These revisions were based on considerations for recent performance trends.

1. Revised figures for the business results forecast for the first half of the fiscal year ending March 31, 2013 (from April 1, 2012, to September 30, 2012)

(Millions of yen / %)

	Net sales	Operating income	Ordinary income	Net income	Net income per share
Previous forecast (A) (May 9, 2012, announcement)	95,100	2,600	2,600	1,200	5.84 yen
Revised forecast (B)	95,100	2,600	2,600	400	1.95 yen
Difference (B – A)	—	—	—	(800)	—
Difference (%)	—	—	—	(66.7)	—
Reference: Previous business results (First half of the fiscal year ended March 31, 2012)	95,478	3,326	3,451	959	4.62 yen

2. Reason for revision

In the first quarter of the fiscal year ending March 31, 2013, the Company recorded loss on valuation of investment securities of ¥697 million under extraordinary loss, as indicated in the Consolidated Financial Statements for the First Quarter Ended June 30, 2012, which were released on July 27, 2012. Moreover, in the six-month period ended September 30, 2012, the Company recorded loss on valuation of investment securities of approximately ¥1 billion under extraordinary loss. As a result, net income for that period is expected to be ¥800 million (66.7%) lower than projected by previous forecasts (released on May 9, 2012).

Further, consolidated subsidiary Takara Bio Inc. (Tokyo Stock Exchange Mothers, securities code number: 4974), which conducts the Biomedical business, also announced revisions to forecasts for the six-month period ended September 30, 2012. However, the impact on the Company's consolidated business results is expected to be minimal.

3. Full-year business results forecast for the fiscal year ending March 31, 2013

The Company is currently evaluating whether or not revisions to forecasts for consolidated business results for the full fiscal year are necessary and the considering the details of possible revisions. The Company will make

an announcement in this regard when it announces its business results for the first half on November 5, 2012.

Further, the full-year forecasts for the fiscal year ending March 31, 2013, released on May 9, 2012, projected the recording of loss on valuation of investment securities of approximately ¥800 million under extraordinary loss on a full year basis.

* The above-mentioned forecasts have been prepared based on the information available as of the date of announcement of this document and could differ from the business result figures scheduled to be announced on November 5, 2012.

Cautionary Statement on the Use of This Document

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.